Financial Shenanigans

Financial Shenanigans — Sonova Holding AG (SOON)

Forensic verdict: 34 / 100 — Watch. Sonova's reported numbers are, on the tests that matter most, a faithful representation of economic reality. Multi-year cash conversion is strong, earnings are backed by cash rather than accrual build, development costs are capitalised conservatively, reserves have risen as volumes fell, and the governance backdrop — Big-4 auditor, unqualified opinion, an all-independent board with no controlling shareholder — actively dampens accounting risk. What keeps this off "Clean" is not distortion but presentation discipline: the group leans heavily on a "normalised EBITA" whose "one-time" add-backs recur every single year and which it is about to redefine again (to "core EBIT"); a chunk of the FY2024/25 operating-cash-flow strength came from a deliberate trade-payables stretch that is now unwinding; and a cluster of impairments and a discontinued-operations loss landed squarely in the CEO-transition-and-divestment year. None of these is a thesis-breaker, each is well disclosed, and the aggregate cash-quality evidence cuts the other way — hence Watch, not Elevated.

Score and flag counts are this analyst's assessment, derived from the evidence cited throughout this page.

Source: derived from reported financials [1] [2]; cash-flow and net-income series as reported in the consolidated statements.

The two live concerns. First, key-metric hygiene (KM1): normalised EBITA has sat above reported EBITA in every one of the last five years, the "one-time" items added back (restructuring, litigation, acquisition amortisation, impairments) recur annually, and from FY2026/27 management moves guidance to a fresh "core EBIT" definition [3]. Second, cash-flow quality (CF4): FY2024/25 operating cash flow was flattered by a payables stretch driven by "payment term initiatives" that lifted Days Payables Outstanding to roughly 90 days, and that tailwind reversed in FY2025/26 [4].

The cleanest offsetting evidence: over FY2021–2025 free cash flow exceeded net income (FCF/NI about 1.05x on a 3-year basis, operating cash flow/NI about 1.28x), the accrual ratio is negative, and capitalised development-cost additions never materially exceeded amortisation while the capitalised balance fell every year — the signature of earnings that are under-, not over-, stated by accrual choices.

The one data point that would most change the grade: evidence that the FY2025/26 Consumer Hearing impairment, or any future write-down of the CHF 2,284.2 million goodwill balance (87% of equity), is masking deterioration in continuing operations would push this toward Elevated; an orderly working-capital normalisation and stable goodwill headroom keep it at Watch [5].

All figures are in Swiss francs (CHF), Sonova's reporting currency. Sonova's fiscal year ends 31 March; "FY2026" denotes the year ended 31 March 2026. Note the reporting quirk: the annual report labelled 2025/26 is the source for FY2026 figures.

The 13-category shenanigans scorecard

The scorecard below is deliberately conservative: a category reads green / no clear evidence only where a specific disclosure supports the pass. Six categories carry a yellow flag; none is red. The weight of the page then goes to the three live ones — non-GAAP hygiene (KM1), the cash-flow mechanism (CF4/KM2), and the transition-year charges (EM7/EM3) — not to equal airtime across all thirteen.

Sources, by row: revenue policy, receivables, inventories, warranty and contract-liability notes of the FY2025/26 report [6] [7] [8]; non-GAAP reconciliation [9]; cash-flow and payables [10]; discontinued operations [11].

Cash generation is real — but name the mechanism

The aggregate cash-quality picture is genuinely strong and is the backbone of the Watch (not Elevated) grade. Operating cash flow has exceeded net income in every year of the window, and free cash flow (operating cash flow less capex) has run at or above net income — cumulative FY2021–2025 free cash flow of roughly CHF 3.42 billion against net income of roughly CHF 3.06 billion. Earnings are cash-backed.

FY2026 operating cash flow is the continuing-operations figure of CHF 734.5m; net income includes the discontinued-operations loss. Source: consolidated cash flow statement and results presentation [12] [13].

The forensic discipline is to ask why cash flow is strong — and here part of the answer is a working-capital lifeline, not just earnings. The FY2024/25 cash-flow statement shows trade payables were a CHF 70.9 million source of cash (versus CHF 11.7 million the prior year); management states plainly that higher receivables and inventories were "more than compensated by the increase in payables, partly due to ongoing payment term initiatives" [14]. That is a deliberate stretch of supplier terms, and it is visible in the days metrics: Days Payables Outstanding climbed from 52 (Sep-22) to 62, then to 72 at 31 March 2024 and 90 at 31 March 2025 [15] [16], while Days Sales Outstanding stayed benign at 54–56 [17]. The working-capital "improvement" that fed operating cash flow came from paying suppliers slower, not from collecting faster.

Year-end days as reported in the results presentations; the 31 Mar 2025 figures were later restated modestly (DPO to 94, DIO to 186) when Consumer Hearing was carved out. Source: FY2024/25 and FY2025/26 results presentations [18] [19].

Crucially, the lifeline is now reversing. By 31 March 2026 DPO fell back to 60, and the FY2025/26 cash-flow statement shows trade payables became a CHF 52.5 million use of cash — a swing of roughly CHF 123 million versus the prior-year source — even as operating cash flow from continuing operations declined 7.1% to CHF 734.5 million [20]. Management still headlines "continued strong cash conversion of above 90%" and a "disciplined balance sheet," and reaffirms a 1.0–1.5x net-debt/EBITDA target [21] [22]. That claim is not being flattered by a payables build in the most recent year — if anything the reversal was a headwind and cash conversion held up on depreciation and lower capex. The forensic point is narrower: do not extrapolate the FY2024/25 cash-conversion strength, because a measurable slice of it was a one-off supplier-terms benefit that has now run its course.

Non-GAAP hygiene: the "one-time" items that arrive every year

This is the most material live flag. Sonova's headline profitability metric is a normalised EBITA that has sat above reported EBITA in each of the last five years — the pattern you expect when "non-recurring" charges are, in fact, recurring.

Source: Five-Year Key Figures table, FY2025/26 Annual Report [23].

The gap is widest in the latest year. FY2026 reported EBITA of CHF 724.2 million is bridged to a normalised CHF 811.2 million by CHF 87.1 million of add-backs, and reported EBIT is lifted from CHF 675.8 million to CHF 762.9 million [24]. The composition is the tell: the same categories — restructuring, transaction/integration, litigation, impairment — appear year after year.

Source: Reconciliation of non-GAAP financial measures and the Non-GAAP Adjustments slide [25] [26].

Restructuring is the clearest example of a "one-time" item that never leaves: CHF 13.5 million (FY2022), 15.6 million (FY2023), 23.7 million (FY2024), 44.2 million (FY2025), and 16.7 million (FY2026) — added back to adjusted profitability every year [27] [28] [29] [30]. Acquisition-related amortisation is excluded on principle and rises each year — from CHF 42.9 million (FY2022) to CHF 57.9 million (FY2025) — so "EBITA" structurally understates the true cost of the group's roll-up strategy [31]. At the segment level the effect is large where it matters: in FY2025, Cochlear Implants reported EBITA of CHF 28.4 million becomes CHF 42.8 million adjusted — a 51% uplift on a small base [32].

Two mitigants keep this yellow rather than red. First, the add-backs are transparently itemised and modest against a roughly CHF 720–810 million EBITA base. Second, management applies the exclusions symmetrically: the CHF 124.4 million one-time patent-award income in FY2020/21 was itself stripped out to reach adjusted EBITA — it was not left in to flatter the headline [33].

The item to watch is the definitional change. From FY2026/27 Sonova moves guidance to a new "core EBIT" that excludes restructuring and special items (M&A and litigation costs) but includes acquisition-related amortisation [34]. A metric change at the same moment as a portfolio reshaping is a standard spot to lose comparability; the base case is that this is a genuine simplification, but it warrants a side-by-side reconciliation against the old bridge for at least two years.

One-off items and the transition-year charges

Reported net income has been repeatedly moved by items that will not repeat — in both directions. The forensic issue is not that any single item is hidden (they are all disclosed) but that a reader who takes reported growth at face value will misjudge the run-rate.

Sources: other-income and tax notes and the discontinued-operations note across the FY2021/22–FY2025/26 reports [35] [36] [37] [38] [39].

The tax-reform line deserves emphasis: the group has excluded a CHF 9.2 million benefit (FY2023), a CHF 39.1 million benefit (FY2024) and then a CHF 49.5 million charge (FY2025) — all under the same "tax reforms" label [40] [41]. Excluding both benefits and reversals is internally consistent, but it means reported EPS swung on items management itself considers non-operational — read the adjusted EPS trend, not the reported one.

The transition-year cluster (EM7) is the softer concern. New CEO Eric Bernard took full charge on 1 October 2025 [42]; in the same fiscal year the Board decided (23 March 2026) to divest the Consumer Hearing business, which was reclassified as a discontinued operation with a CHF 106.5 million after-tax loss, including a CHF 38.3 million pre-tax impairment first allocated to goodwill (CHF 16.2 million) [43] [44]. A CHF 34.7 million software impairment landed in the same year [45]. This is the textbook window for a big bath: new leadership, a strategic exit, comparatives restated. The countervailing facts are that the divestment is a real strategic decision, the impairments trace to genuine value loss (a loss-making consumer unit; software that "will no longer deliver the economic benefits originally anticipated" [46]), and the auditor did not flag them as a key audit matter. The flag is on the timing and clustering, not on the existence of the charges.

The clean tests — stated plainly, and cited

Clean negative evidence is what makes the yellow flags credible. Four important tests pass on the primary record.

Revenue recognition (EM1) — clean. Revenue is recognised point-in-time on transfer of control (mainly delivery; for retail, after fitting or when the trial period lapses), with an explicit returns provision estimated from historical return rates; 96% of FY2026 sales (CHF 3,464.5m of CHF 3,605.9m) are recognised point-in-time, consistent with a product company [47]. Contract-liability (deferred-revenue) movements are routine — CHF 134.1 million of new advance consideration in versus CHF 115.2 million of opening balance released — with no suspicious drawdown to prop up sales [48].

Reserving (EM5) — clean, and if anything conservative. As volumes fell, reserves rose. The doubtful-receivables allowance increased to CHF 27.2 million (from 25.6m) even as gross receivables fell to CHF 554.5 million (from 602.5m) — coverage up from 4.2% to 4.9% [49]. Inventory obsolescence write-downs rose to CHF 24.9 million (from 20.4m) despite lower inventory [50], and warranty-and-returns provision increases (CHF 79.4m) dwarfed reversals (CHF 20.3m) [51]. There is no evidence of starving reserves to flatter margin.

Capitalisation (EM4 / CF2) — clean, and de-risking. Sonova capitalises internally-generated development costs (chiefly cochlear-implant software, amortised over 2–7 years [52]), but the additions ran well below amortisation in FY2022–FY2024 and only marginally above it in FY2025–FY2026 (the largest excess is under CHF 1 million) — never the "capitalise to defer costs" build you would flag. Net book value has fallen every single year, nearly halving from CHF 148.5 million to CHF 80.9 million.

Additions ran well below amortisation in FY2022–FY2024 and roughly in line with it (marginally above) in FY2025–FY2026, while net book value fell every year (from CHF 125.9m at FY2022-start to CHF 80.9m). Source: Note 3.5 Intangible assets roll-forwards, FY2021/22–FY2025/26 [53] [54].

Cash-flow classification (CF1) — clean. The receivables and financing notes disclose no factoring, securitisation, or with-recourse receivable sales, so operating cash flow is not borrowed cash dressed up as operations [55].

Breeding ground: the governance backdrop dampens the flags

The structural conditions that make shenanigans more likely are largely absent here, which is why the accounting flags stay yellow.

• Auditor. Ernst & Young issued an unqualified, true-and-fair opinion on the FY2025/26 statements [56]. Tenure is a moderate six years (first elected 2020), and non-audit fees are only about 10% of the total (CHF 0.35m of CHF 3.36m), governed by a formal Audit Committee policy — all independence-supportive [57]. The two key audit matters are the judgment-heavy areas a forensic reader would pick: goodwill (CHF 2,284.2m, or 87% of equity) and product-liability provisions (CHF 36.5m, mainly the 2020 Advanced Bionics field action) [58].
• Board and ownership. The board is fully independent and non-executive, chair and CEO roles are separate, and a three-member all-independent Audit Committee meets four times a year [59]. There is no controlling shareholder: the founder-linked blocks (Beda Diethelm 11.26%, Rihs family 6.18%) hold no shareholders' agreement and can trade freely [60].
• Related parties. The related-party note discloses only key-management compensation (CHF 12.0m) — no material transactions, and explicitly no director or executive loans [61].
• Incentives. Pay is diversified across Group sales, EBITA, free cash flow and EPS (short-term) and ROCE plus relative TSR (long-term), with caps and multi-year vesting — balanced rather than skewed to a single manipulable adjusted metric, and FY2025/26 payouts landed near target (CEO 109.4%) [62].

The one way the breeding ground amplifies rather than dampens: the CEO transition plus the March 2026 divestment created the classic big-bath window discussed above, and two long-tenured Audit Committee members (Bleil and van der Vis) are stepping down at the June 2026 AGM alongside a record dividend proposal of CHF 4.70 — a modest continuity risk worth monitoring [63].

What to underwrite next

Five specific, named items to track into the FY2026/27 interim and annual report:

1. Working-capital days (CF4). Watch DPO and the trade-payables line in the next two cash-flow statements. A downgrade signal: operating cash flow held up only by a renewed payables stretch (DPO climbing back toward 90) rather than earnings. An upgrade signal: DPO stabilising near 60 with operating cash flow still converting above 85% of adjusted profit. Source line: "Decrease/(increase) in trade payables" in the consolidated cash flow statement [64].
2. The core-EBIT redefinition (KM1). Demand a two-year side-by-side of "core EBIT" against the old normalised-EBITA bridge. Downgrade if the new metric quietly moves recurring costs (e.g., integration or platform-launch spend) into the excluded bucket; upgrade if reported-to-core reconciliation is stable and complete [65].
3. Goodwill headroom (KM2). Goodwill of CHF 2,284.2m is 87% of equity; track the impairment-test disclosures and any narrowing of headroom, especially in Cochlear Implants after the China volume-based-procurement hit [66].
4. Discontinued-operations completion (EM7 / CF3). Confirm the Consumer Hearing divestment closes near the CHF 38.3m written-down carrying value, and that continuing-operations margins do not simply inherit the flattered comparatives. Watch for any further "one-time" charges recognised before completion [67].
5. Restructuring recurrence (KM1). If a fresh restructuring charge appears in FY2026/27 — as it has in every recent year — it confirms these are operating costs, not one-offs; size it against the CHF 16.7–44.2m range of the last five years [68].

Bottom line. For a PM, Sonova's accounting risk is a valuation-and-metrics footnote, not a thesis breaker. The economics look faithfully reported: cash conversion is strong, earnings are cash-backed, capitalisation is conservative, reserves are ample, and governance is a genuine control rather than a rubber stamp. The discipline this analysis imposes is on how you read the headline: value the business on reported EBIT and cash flow adjusted for the recurring "one-time" items and the now-unwinding payables benefit, not on the normalised metrics management leads with — and keep the CEO-transition-year charges and the imminent metric redefinition on a short leash. That argues for a normal margin of safety and standard position sizing, not a covenant or fraud-risk haircut.